Can you get medical cannabis for ADHD in the UK?

ADHD is one of the fastest-growing reasons people approach private clinics, and one of the weakest areas of evidence in the whole field. Both of those things are worth knowing before you spend money on a consultation.

The short answer

  • ADHD is assessed privately in the UK, but no cannabis-based product is licensed for it.
  • The only randomised trial did not meet its primary endpoint.
  • Licensed ADHD medicines come first. A specialist will expect those to have been tried.
  • Diagnosis matters enormously here. A formal ADHD assessment is normally a precondition.
  • THC can impair attention and memory — the same functions ADHD already affects.

Is ADHD treated with medical cannabis in the UK?

It is assessed privately, and the number of people asking about it has risen sharply. It is not an NHS treatment, no cannabis-based product is licensed for ADHD, and NICE guidance on ADHD does not include cannabis-based medicines among the treatments it recommends.

The rise in enquiries has a straightforward explanation that has nothing to do with the evidence: NHS adult ADHD assessment waiting lists in parts of the UK run to several years, and the licensed stimulant medicines have been subject to repeated supply shortages. People who cannot get assessed, or cannot get their usual medicine, look for alternatives.

That is an understandable reason to ask the question. It is not, on its own, a clinical reason for a specialist to answer yes.

What the evidence actually shows

There is one randomised controlled trial. It did not meet its primary endpoint. Everything else is observational, and observational data cannot separate a real effect from the relief of being treated at all.

The trial randomised thirty adults with ADHD to a cannabinoid oromucosal spray or placebo over six weeks. The primary outcome — a cognitive performance measure — did not reach statistical significance. Some secondary symptom measures showed improvement, which the authors themselves described as a signal worth testing properly rather than a result to act on.

The study behind that paragraph

Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial. European Neuropsychopharmacology. 2017;27(8):795-808. A six-week pilot RCT in 30 adults. The primary cognitive outcome was not met; the authors called for a larger trial.

Read the paper →

A large systematic review of cannabinoids across mental health conditions reached the same conclusion for ADHD as it did for most psychiatric indications: there is not enough controlled evidence to support routine use. UK registry data reports symptom improvements in people prescribed for ADHD, with the usual caveat that people who stay in treatment and complete questionnaires are not a random sample of everyone who started.

What a specialist will want to see

There is no UK list of qualifying conditions, so nothing here entitles you to a prescription. For ADHD specifically, the diagnosis itself is usually the first thing examined, because a large proportion of enquiries come from people who have not yet been formally assessed.

A specialist who offers to prescribe for ADHD without a diagnosis, or without your records, is not assessing you. That is one of the clearer warning signs described in Can I get medical cannabis for myself in the UK?

The general requirements — age, a documented diagnosis, the convention that two standard treatments have been tried, and access to your medical records — are covered in What are the requirements?

Risks and reasons a specialist may say no

This is the condition where the risk profile most directly contradicts the reason people ask. THC impairs sustained attention, working memory and reaction time in the short term — the exact functions ADHD already disrupts.

ADHD also carries an elevated baseline risk of substance use problems, which makes a careful specialist more cautious rather than less. Where ADHD coexists with a personal or family history of psychosis, that will normally count decisively against treatment.

The ordinary cautions apply too: drowsiness, dizziness, dry mouth, and driving impairment. Driving is covered in Can you drive on a medical cannabis prescription?

If you want to take this further

The useful next step is a proper assessment, not a longer reading list. Gather your diagnosis, the treatments you have already tried and what happened with each, and a current list of your medicines — that is what a specialist needs in order to give you a straight answer.

The consultation itself, and what happens after it, is set out in What is the process to get a medical cannabis prescription? If ADHD is not the only thing you are being treated for, say so early: other conditions and other medicines change the assessment.

Frequently asked questions

Can I get medical cannabis for ADHD in the UK?

You can be assessed for it privately. No cannabis-based product is licensed for ADHD, NICE guidance on ADHD does not recommend it, and the single randomised trial did not meet its primary endpoint. A specialist will normally expect licensed ADHD medicines to have been tried first.

Can I get it if I am still on the NHS ADHD waiting list?

Usually not. Most specialists treat a formal ADHD diagnosis as a precondition, because without one there is nothing to treat and no way to judge whether symptoms have another cause. A private ADHD assessment is a separate process from a medical cannabis consultation.

What if stimulant medication is out of stock?

Supply problems are a real difficulty, but they are not a clinical indication in themselves. A specialist will look at whether a licensed alternative is available and appropriate before considering an unlicensed medicine.

Does it help focus?

The controlled evidence does not show that. THC impairs sustained attention and working memory in the short term. Some people report subjective improvement, which observational data reflects, but that data cannot separate a drug effect from other explanations.

Sources and further reading

Every factual statement on this page is drawn from the following public sources. Links open in a new tab and are not affiliated with Flora House.

  1. Cooper RE, et al. Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial. European Neuropsychopharmacology (2017)
  2. Black N, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry (2019)
  3. NICE guideline NG87: Attention deficit hyperactivity disorder — diagnosis and management
  4. NICE guideline NG144: Cannabis-based medicinal products
  5. NHS: Medical cannabis (and cannabis oils)
  6. MHRA: The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use

Patient guide · Written by the Flora House editorial team · Last reviewed: 8 September 2026